secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001193125-22-299797
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio reports initial clinical proof-of-concept for trem-cel; first AML patient engrafts normally
--------------------------------------------------------------------------------

- First patient received trem-cel dose of 7.6x10^6 CD34+ cells/kg with 88% CD33 editing efficiency.
- Neutrophil engraftment at 10 days, platelet recovery Day 22; >90% of PBMCs CD33-negative, 100% donor chimerism.
- No infusion reactions or treatment-related adverse events observed post-transplant.
- Mylotarg 0.5 mg/m^2 tolerated with no neutropenia or liver enzyme changes through Day 20.
- Trial continues enrolling; additional data expected in 2023; conference call Dec 7 at 8am ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/0001193125-22-299797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/d431519d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-299797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer